Ge
No verificado

Genethon

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud
14/01/2026
Voluntariado/Solidaridad/ONGs
Mercado laboral
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Genethon Signs Licensing Agreement With AskBio for the Development of an Investigational Gene Therapy for Pompe Disease
1.00
06/01/2026
Eventos
Web y redes sociales
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Genethon Management to Host Partnering Meetings During JP Morgan Healthcare Week, January 12 -16, 2026 in San Francisco, CA
1.00
10/10/2025
Multimedia
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Eventos
Ferias y Congresos
Industria
Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
1.00
09/10/2025
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Web y redes sociales
Voluntariado/Solidaridad/ONGs
Eventos
Industria
Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress
1.00
28/07/2025
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
1.00
27/02/2025
Salud
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Farmacéutica
Industria
Genethon Celebrates Rare Disease Day by Highlighting New Technologies to Advance Gene Therapies and Bring Hope to Millions of Patients Worldwide
1.00
19/12/2024
Técnica
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Voluntariado/Solidaridad/ONGs
Industria
A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon’s 2024 Fall Milestones
1.00
03/12/2024
Multimedia
Industria
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0